MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing a voice-based artificial intelligence platform designed to rapidly detect drug and alcohol impairment from short speech samples, offering a non-invasive alternative to traditional breath, saliva, urine and laboratory-based testing. The technology, trained on more than 50 million data points and analyzing over 140 acoustic markers, aims to deliver real-time impairment assessments through Edge AI kiosks, with initial field testing planned in 2026.
The company's initial commercial focus is on South American mining operations, where large-scale workforce screening presents significant safety and logistical challenges. As the global alcohol and drug testing devices market is projected to grow from approximately $2.5 billion in 2025 to $4.2 billion by 2033, MindBio sees opportunities to expand its platform into aviation, construction, transportation, law enforcement, call centers and healthcare, leveraging its proprietary research to address the increasing demand for faster, scalable workplace impairment detection.
According to the company, the AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The platform includes Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication in a range of enterprise environments. This technology could significantly reduce the time and cost associated with current testing methods, which often require invasive sample collection and laboratory analysis.
For leaders in industries with high safety standards, such as mining and aviation, the ability to quickly and accurately assess impairment could transform workplace safety protocols. The non-invasive nature of voice analysis may also improve compliance and reduce resistance from employees. Additionally, the scalability of Edge AI kiosks allows for deployment in remote locations, making it particularly valuable for operations in isolated areas.
The potential impact extends beyond workplace safety. Law enforcement agencies could use the technology for roadside impairment testing, while call centers and healthcare facilities might integrate it to ensure employee fitness for duty. However, the technology's accuracy and reliability will need to be validated through field testing before widespread adoption. The company's planned 2026 field tests will be critical in demonstrating its effectiveness in real-world conditions.
For more information on MindBio Therapeutics, visit the company's newsroom at https://ibn.fm/MBQIF. The full article detailing the announcement is available at https://ibn.fm/Gw5Fa.
